|
Sánchez-del-Campo L., Chazarra S., Montenegro M., Cabezas-Herrera J., Rodríguez-López J. Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin. Journal of Cellular Biochemistry. 15 August 2010. 110:1399-1409. 10.1002/jcb.22656
AÑO: 2010; IF: 3.122
|
20564235
|
Sánchez-del-Campo L., Sáez-Ayala M., Chazarra S., Cabezas-Herrera J., Rodríguez-López J.N. Binding of natural and synthetic polyphenols to human dihydrofolate reductase. International Journal of Molecular Sciences. December 2009. 10:5398-5410. 10.3390/ijms10125398
AÑO: 2009; IF: 1.387
|
|
Sánchez-del-Campo L., Tárraga A., Montenegro M., Cabezas-Herrera J., Rodríguez-López J. Melanoma activation of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase. Molecular Pharmaceutics. 1 June 2009. 6:883-894. 10.1021/mp800259k
AÑO: 2009; IF: 5.408
|
|
Sánchez-del-Campo L., Rodríguez-López J.N. Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin. International Journal of Cancer. 15 November 2008. 123:2446-2455. 10.1002/ijc.23813
AÑO: 2008; IF: 4.734
|
|
Navarro-Perán E., Cabezas-Herrera J., Sánchez-Del-Campo L., García-Cánovas F., Rodríguez-López J.N. The anti-inflammatory and anti-cancer properties of epigallocatechin-3- gallate are mediated by folate cycle disruption, adenosine release and NF-κB suppression. Inflammation Research. October 2008. 57:472-478. 10.1007/s00011-008-8013-x
AÑO: 2008; IF: 1.457
|